Daily Trades

The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
Thirty years of investing has taught me that when it’s time to sell, it’s time to sell. There’s no point in crying about it.
In April, we sold half of our shares in Apellis Pharmaceuticals, Inc (SYM: APLS) at $85, a 76% increase from our recommended price of $48.42. 
Let's start by closing out one of our older positions for a small profit. 
I recommend selling half your shares in Apellis Pharmaceuticals, Inc (SYM: APLS)
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it. 
A lot of folks have written in to ask if we think Apellis Pharmaceuticals (SYM: APLS) is a still buy. We recommended shares at $48.42 on January 13, and watched it explode to a high of $70.75, or, 46% in less than two months. Shares are now at $65, after the market sell-off.
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population). As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.

deal of the month

best growth stocks

Alliance

Bundle package – lifetime subscriptions for all products

Categories

Recent posts

Tags

Connect with Us

The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
Thirty years of investing has taught me that when it’s time to sell, it’s time to sell. There’s no point in crying about it.
In April, we sold half of our shares in Apellis Pharmaceuticals, Inc (SYM: APLS) at $85, a 76% increase from our recommended price of $48.42. 
Let's start by closing out one of our older positions for a small profit. 
I recommend selling half your shares in Apellis Pharmaceuticals, Inc (SYM: APLS)
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it. 
A lot of folks have written in to ask if we think Apellis Pharmaceuticals (SYM: APLS) is a still buy. We recommended shares at $48.42 on January 13, and watched it explode to a high of $70.75, or, 46% in less than two months. Shares are now at $65, after the market sell-off.
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population). As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.